Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Covalent Tolerance Induction to Factor VIII-Prediction of Inhibitors in Hemophilia

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Miguel Escobar, The University of Texas Health Science Center, Houston
ClinicalTrials.gov Identifier:
NCT00178607
First received: September 12, 2005
Last updated: May 10, 2016
Last verified: May 2016

September 12, 2005
May 10, 2016
August 2002
October 2015   (final data collection date for primary outcome measure)
Inactivation of antibodies by the FVIII covalent reactive analogs [ Time Frame: 6 months ] [ Designated as safety issue: No ]
Not Provided
Complete list of historical versions of study NCT00178607 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Covalent Tolerance Induction to Factor VIII-Prediction of Inhibitors in Hemophilia
Covalent Tolerance Induction to Factor VIII-Prediction of Inhibitors in Hemophilia
To correlate the Human Leukocyte Antigen type and genetic defect with hemophilia A.
One of the most serious complications of treatment in patients with hemophilia A or hemophilia B is the development of an inhibitor, which is an antibody that neutralizes the factor VIII or IX coagulant activity. Up to one fourth of patients with severe hemophilia A develop an inhibitor but at present it is not possible to predict which patients will develop such antibody. The ability to predict an inhibitor development at an individual level would greatly improve therapeutic approach to this serious problem
Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
Description:
Serum and Plasma
Probability Sample
Subjects with Severe Hemophilia A and a positive inhibitor
Hemophilia A
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
99
October 2015
October 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Severe Hemophilia A with an inhibitor level of 0.6 B.U. or higher

Exclusion Criteria:

  • Severe Hemophilia A with a negative inhibitor
Male
up to 99 Years   (Child, Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00178607
Inhibitors
No
Yes
The data will be analyzed and published
Miguel Escobar, The University of Texas Health Science Center, Houston
The University of Texas Health Science Center, Houston
Not Provided
Principal Investigator: Miguel Escobar, MD The University of Texas Health Science Center, Houston
The University of Texas Health Science Center, Houston
May 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP